{"url_path":"/sec/anro/8-k/2026-07-13/item-8-01","section_key":"item-8-01","section_title":"Item 8.01 ****Other Events.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-13","source_url":"https://www.sec.gov/Archives/edgar/data/1999480/0001104659-26-082875-index.html","accession_number":"0001104659-26-082875","cik":"0001999480","ticker":"ANRO","issuer_name":"Alto Neuroscience, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1999480/0001104659-26-082875-index.html","primary_entity_key":"0001999480","primary_entity_name":"Alto Neuroscience, Inc."},"word_count":417,"has_tables":true,"body_markdown":"** **\n\n**Item 8.01****Other Events.**\n\n* *\n\n*Cash, Cash Equivalents and Restricted Cash as of June 30, 2026*\n\n* *\n\nOn July 13, 2026, Alto Neuroscience, Inc. (the\n“**Company**”) announced that, based upon preliminary estimates and information available to the Company, it estimates\nthat its cash, cash equivalents and restricted cash were approximately $244.2 million as of June 30, 2026. This amount has not been audited,\nreviewed, or compiled by the Company’s independent registered public accounting firm. The Company’s actual cash, cash equivalents\nand restricted cash as of June 30, 2026 may differ from these amounts after it completes its comprehensive accounting procedures for the\nquarter ended June 30, 2026, and any such differences may be material.\n\n \n\n*Pipeline Update*\n\n \n\nThe Company intends to accelerate and expand the\nclinical development of its most advanced program, ALTO-207, including to conduct an additional planned Phase 3 trial of ALTO-207 as monotherapy\nfor the treatment of treatment-resistant depression.\n\n \n\n**Forward-Looking Statements**\n\n \n\nThis Current Report on Form 8-K contains forward-looking\nstatements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “anticipates,” “believes,”\n“expects,” “intends,” “projects,” “plans,” and “future” or similar expressions\nare intended to identify forward-looking statements. Forward-looking statements include statements concerning the Company’s clinical\ndevelopment plans for ALTO-207, and other statements that are not historical fact. Forward-looking statements are based on management’s\ncurrent expectations and are subject to various risks and uncertainties that could cause actual results to differ materially and adversely\nfrom those expressed or implied by such forward-looking statements. Accordingly, these forward-looking statements do not constitute guarantees\nof future performance, and you are cautioned not to place undue reliance on these forward-looking statements. Risks regarding the Company’s\nbusiness are described in detail in its SEC filings, including in the Company’s Annual Report on Form 10-K for the year ended December\n31, 2025 and other filings that the Company may make with the SEC, which are available on the SEC’s website at www.sec.gov. Additional\ninformation will be made available in other filings that the Company makes from time to time with the SEC. These forward-looking statements\nspeak only as of the date hereof, and the Company disclaims any obligation to update these statements except as may be required by law.\n\n \n\n \n\n \n\n \n\n**SIGNATURES**\n\n \n\nPursuant to the requirements of the Securities Exchange Act of 1934,\nthe registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n**ALTO NEUROSCIENCE, INC.**\n\n \n \n \n\nDated: July 13, 2026\nBy:\n/s/ Amit Etkin\n\n \n \nAmit Etkin, M.D., Ph.D.\n\n \n \nPresident and Chief Executive Officer"}